SLN SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 10, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 8, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany

Oct 19, 2026

8-K

Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares

Aug 12, 2026

8-K

Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera

Aug 10, 2026

8-K

Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

Aug 10, 2026

8-K/A

Executive Separation Agreement Includes $655,000 Salary Continuation, $250,000 Severance, and Additional Benefits for Former Officer

Jul 16, 2026

8-K

Silence Therapeutics June 2026 Corporate Presentation: Divesiran and SLN312 Pipeline Updates

Jun 23, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Aug 12, 2026

424B5

PENDING FIXED PRICE OFFERING | Offering amount: $150,000,000 | Bank: Jefferies, Morgan Stanley, Cantor, William Blair

Aug 10, 2026

424B5

[No Baby Shelf]* May 2026 ATM | Offering amount: $100,000,000 | Bank: Jefferies LLC

May 27, 2026

424B3

UPDATED

May 14, 2024

424B5

SHELF OFFERING | Shares amount: 17,850,000 | Share price: $9.50 | Offering amount: $56,525,000.00 | Bank: MORGAN STANLEY, WILLIAM BLAIR

Aug 12, 2022

424B5

Up to $100,000,000-

Oct 22, 2021

Registrations

TYPE

HEADLINE

FILED AT

S-3MEF

August 2026 SHELF

Aug 11, 2026

S-3

May 2026 SHELF + ATM

May 18, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 5, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 27, 2025

F-3ASR

October 2024 SHELF + ATM

Oct 22, 2024

F-3

SHELF EFFECTIVE, DATED 2024-05-14

May 7, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Oct 19, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Oct 19, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

May 16, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

May 6, 2025

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G

FMR LLC (Filed by)

Nov 5, 2026

SCHEDULE 13G/A

Tetragon Financial Management LP (Filed by)

Oct 13, 2026

SCHEDULE 13G

Tetragon Financial Management LP (Filed by)

Oct 13, 2026

SCHEDULE 13D/A

Griffiths Richard Ian (Filed by)

Aug 13, 2026

SCHEDULE 13G/A

Invus Global Management, LLC (Filed by)

Aug 13, 2026

Griffiths Richard Ian (Reporting)

Aug 13, 2026

Other

TYPE

HEADLINE

FILED AT

Silence Therapeutics plc SLN · SEC Filings